Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof-of-Concept study of GTP-011 (Scopolamine) for the treatment of symptoms of motion sickness.

Trial Profile

Proof-of-Concept study of GTP-011 (Scopolamine) for the treatment of symptoms of motion sickness.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Scopolamine (Primary)
  • Indications Motion sickness
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting, according to a GT Biopharma media release.
    • 06 Apr 2018 New trial record
    • 29 Mar 2018 According to the GT Biopharma media release, this trial was initiated in late February 2018 and more than 50% patient has been enrolled in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top